Literature DB >> 21548602

Elucidation of the Hsp90 C-terminal inhibitor binding site.

Robert L Matts1, Anshuman Dixit, Laura B Peterson, Liang Sun, Sudhakar Voruganti, Palgunan Kalyanaraman, Steve D Hartson, Gennady M Verkhivker, Brian S J Blagg.   

Abstract

The Hsp90 chaperone machine is required for the folding, activation, and/or stabilization of more than 50 proteins directly related to malignant progression. Hsp90 contains small molecule binding sites at both its N- and C-terminal domains; however, limited structural and biochemical data regarding the C-terminal binding site is available. In this report, the small molecule binding site in the Hsp90 C-terminal domain was revealed by protease fingerprinting and photoaffinity labeling utilizing LC-MS/MS. The identified site was characterized by generation of a homology model for hHsp90α using the SAXS open structure of HtpG and docking the bioactive conformation of NB into the generated model. The resulting model for the bioactive conformation of NB bound to Hsp90α is presented herein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21548602      PMCID: PMC3164513          DOI: 10.1021/cb200052x

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  40 in total

1.  High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.

Authors:  Lakshmi Galam; M Kyle Hadden; Zeqiang Ma; Qi-Zhuang Ye; Bo-Geon Yun; Brian S J Blagg; Robert L Matts
Journal:  Bioorg Med Chem       Date:  2007-01-04       Impact factor: 3.641

Review 2.  The Hsp90 molecular chaperone: an open and shut case for treatment.

Authors:  Laurence H Pearl; Chrisostomos Prodromou; Paul Workman
Journal:  Biochem J       Date:  2008-03-15       Impact factor: 3.857

3.  Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.

Authors:  Joseph A Burlison; Christopher Avila; George Vielhauer; Donna J Lubbers; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  J Org Chem       Date:  2008-02-23       Impact factor: 4.354

4.  Structural models and binding site prediction of the C-terminal domain of human Hsp90: a new target for anticancer drugs.

Authors:  Miriam Sgobba; Gianluca Degliesposti; Anna Maria Ferrari; Giulio Rastelli
Journal:  Chem Biol Drug Des       Date:  2008-03-25       Impact factor: 2.817

Review 5.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

6.  Apo-Hsp90 coexists in two open conformational states in solution.

Authors:  Patrick Bron; Emmanuel Giudice; Jean-Paul Rolland; Rubén M Buey; Pascale Barbier; J Fernando Díaz; Vincent Peyrot; Daniel Thomas; Cyrille Garnier
Journal:  Biol Cell       Date:  2008-07       Impact factor: 4.458

7.  Conserved conformational changes in the ATPase cycle of human Hsp90.

Authors:  Klaus Richter; Joanna Soroka; Lukasz Skalniak; Adriane Leskovar; Martin Hessling; Jochen Reinstein; Johannes Buchner
Journal:  J Biol Chem       Date:  2008-04-09       Impact factor: 5.157

Review 8.  Hsp90: a novel target for the disruption of multiple signaling cascades.

Authors:  Stephanie C Bishop; Joseph A Burlison; Brian S J Blagg
Journal:  Curr Cancer Drug Targets       Date:  2007-06       Impact factor: 3.428

9.  Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90.

Authors:  Kristin A Krukenberg; Friedrich Förster; Luke M Rice; Andrej Sali; David A Agard
Journal:  Structure       Date:  2008-05       Impact factor: 5.006

10.  Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle.

Authors:  Daniel R Southworth; David A Agard
Journal:  Mol Cell       Date:  2008-12-05       Impact factor: 17.970

View more
  47 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 2.  GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum.

Authors:  Michal Marzec; Davide Eletto; Yair Argon
Journal:  Biochim Biophys Acta       Date:  2011-11-03

3.  Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity.

Authors:  Bhaskar Reddy Kusuma; Liang Zhang; Teather Sundstrom; Laura B Peterson; Rick T Dobrowsky; Brian S J Blagg
Journal:  J Med Chem       Date:  2012-06-15       Impact factor: 7.446

4.  A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.

Authors:  Mathias Riebold; Christian Kozany; Lee Freiburger; Michael Sattler; Michael Buchfelder; Felix Hausch; Günter K Stalla; Marcelo Paez-Pereda
Journal:  Nat Med       Date:  2015-02-09       Impact factor: 53.440

5.  Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities.

Authors:  Elisabetta Moroni; Huiping Zhao; Brian S J Blagg; Giorgio Colombo
Journal:  J Chem Inf Model       Date:  2014-01-15       Impact factor: 4.956

6.  Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor.

Authors:  Anuj Khandelwal; Jessica A Hall; Brian S J Blagg
Journal:  J Org Chem       Date:  2013-08-01       Impact factor: 4.354

Review 7.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

8.  Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity.

Authors:  Zheng Zhang; Zhenyuan You; Rick T Dobrowsky; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2018-03-26       Impact factor: 2.823

9.  Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail.

Authors:  Suman Ghosh; Yang Liu; Gaurav Garg; Mercy Anyika; Nolan T McPherson; Jiacheng Ma; Rick T Dobrowsky; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2016-07-05       Impact factor: 4.345

10.  Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Anuj Khandelwal; Wen Gu; Douglas Brown; Weiya Liu; George Vielhauer; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.